Replies to post #114206 on Amarantus Bioscience Holdings Inc (AMBS)

[Jellyfish]

Again in the 10q it states

"The second step [after the Lonza option is consummated] in the acquisition of ESS required the Company to enter into an Asset Purchase Agreement (the “Regenicin APA”) with Regenicin, Inc. (“Regenicin”) including (i) rights to a lawsuit that Regenicin brought against Lonza (the “Litigation”), and (ii) all intellectual property rights held by Regenicin related to any engineered skin technology for the treatment of severe burns in humans, including any related trademarks."

Therfore if the ESS deal does not get done, AMBS gets nothing and loses all the money and shares that AMBS payed for the option.